News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 19, 2024
- Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and...
-
Feb 27, 2024
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Feb 7, 2024
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Feb 2, 2024
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Feb 1, 2024
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Dec 22, 2023
- Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300- - Received FDA feedback on TYRA-300...
-
Nov 8, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Nov 7, 2023
- Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patient to be dosed in...
-
Sep 21, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Sep 12, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Aug 10, 2023
-Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first...
-
Aug 1, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
May 25, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
May 4, 2023
-SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023- -Strong...
-
Mar 29, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor...
-
Mar 22, 2023
-Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia- -Cleared IND for...
-
Mar 1, 2023Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024- -Conference...
-
Feb 22, 2023
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 29, 2022
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ -- Tyra...
-
Nov 10, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 3, 2022
-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD,...
-
Nov 2, 2022
-Esther van den Boom to transition to an advisor at year-end 2022- -Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:...
-
Oct 13, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 8, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 5, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Aug 4, 2022
-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1...
-
May 5, 2022
-Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARLSBAD, Calif., May 5, 2022 /PRNewswire/...
-
Mar 3, 2022-Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022-
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Feb 22, 2022
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 10, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Nov 3, 2021-Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021-
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 27, 2021
Tyra is striving to excel in three areas: crystallography, cell-based assays and in-vivo models CEO: Todd Harris Based: Carlsbad, California Founded: 2018 Clinical focus: Overcoming acquired drug...
-
Sep 17, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Sep 14, 2021
Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...
-
Mar 31, 2021– Financing led by Nextech Invest with participation from Cormorant Asset Management, BVF Partners, L.P., Janus Henderson Investors, and Logos, along with existing investors Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan
CARLSBAD, Calif., Mar. 31, 2021 — Tyra Biosciences, a biotech company targeting acquired resistance in oncology with purpose-built drugs, today announced the closing of a $106 million Series B...
-
Jan 10, 2020– Round co-led by Alta Partners, RA Capital, Boxer Capital of Tavistock Group, and Canaan, representing a group of seasoned early-stage and crossover investors
CARLSBAD, Calif., Jan. 10, 2020 — Today Tyra Biosciences announced a Series A financing of $50M to discover and develop new small molecule therapies targeting acquired resistance in oncology....